Efferon secures €2.5M to grow blood purification platform

2026-05-21 · Source: Tech.eu - Tech.eu · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Clinical Care & Medical Practice, Medical Devices & Health Technology · Depth: Fundamental Awareness, quick

Summary

Biotech company Efferon has secured €2.5 million in a seed funding round, led by private investors from the DACH region, to expand the European commercial presence of its hemoadsorption devices. These devices, including Efferon LPS and the pediatric Efferon NEO, are designed to remove endotoxins and inflammatory mediators from the bloodstream to treat sepsis, septic shock, and other inflammation-related conditions. The funding will specifically support the construction of a new EU production facility and increase manufacturing capacity for Efferon LPS. Efferon NEO recently received CE MDR certification, making it the first hemoadsorption device in Europe approved for neonatal and pediatric sepsis patients, supported by the LASSO NEO study. The company reports its technology has been used in over 25,000 treatments across more than 40 countries, aiming to reduce ICU costs and address the 11 million annual sepsis deaths worldwide.

Key takeaway

For healthcare investors evaluating biotech opportunities, Efferon's €2.5 million seed round and CE MDR certification for its pediatric hemoadsorption device highlight a validated solution addressing critical care needs. You should consider the market potential for technologies that reduce ICU treatment costs and target underserved patient populations like neonates with sepsis. This investment signals growing confidence in specialized blood purification platforms for acute and potentially chronic inflammatory conditions.

Key insights

Efferon's hemoadsorption devices provide a certified solution for sepsis and septic shock, including a first-in-Europe pediatric version.

Principles

• Sepsis is a major global health priority.
• Hemoadsorption can reduce ICU treatment costs.
• Systemic inflammation impacts chronic diseases.

In practice

• Treat sepsis and septic shock.
• Apply to neonatal and pediatric patients.
• Explore chronic disease applications.

Topics

• Hemoadsorption
• Sepsis Treatment
• Biotech Funding
• CE MDR Certification
• Pediatric Care
• Critical Care Devices

Best for: Investor, Entrepreneur, Domain Expert

Related on AIssential

• Tissium raises €30M in equity funding, €30M in debt — Tissium's biomorphic programmable polymers offer a non-invasive tissue repair solution, securing significant funding for US expansion.
• HemExp: Clinically-Guided Latent Diffusion for Modeling Hematoma Expansion — HemExp uses clinically-guided latent diffusion to generate patient-specific CT images, predicting hematoma expansion and providing uncertainty-aware outcomes.
• Alesi Surgical raises £7M to clear the air in operating theatres with next-gen smoke management tech — Electrostatic precipitation offers superior surgical smoke clearance, enhancing safety and efficiency in operating theatres.
• Stripe, Anthropic, and OpenAI are backing an effort to stop respiratory infections — Private philanthropy can drive solutions for technically possible problems lacking commercial incentives, like preventing respiratory viruses.
• China has approved the world’s first invasive brain-computer chip—here’s what’s next — China's NEO BCI, less invasive and government-backed, is the first globally approved for commercial use, offering hope for paralysis patients.
• Fully Open Meditron: An Auditable Pipeline for Clinical LLMs — Fully open pipelines enable auditable, reproducible, and high-performing LLM-based clinical decision support systems.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Tech.eu - Tech.eu.